Prothena Corporation plc announced that pursuant to its license, development, and commercialization agreement with Roche, it will receive the $30 million upfront payment from Roche as a result of the license agreement having become effective upon the expiration of the Hart-Scott-Rodino waiting period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.88 USD | -1.06% |
|
+13.64% | -34.30% |
07-01 | Prothena Corporation plc(NasdaqGS:PRTA) added to Russell Small Cap Comp Value Index | CI |
07-01 | Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 2500 Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.30% | 1.3B | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- PRTA Stock
- News Prothena Corporation plc
- Prothena Corporation plc to Receive $30 Million Upfront Payment from Roche Triggered by the Expiration of Hart-Scott-Rodino Waiting Period